FL1
MCID: FLL041
MIFTS: 49

Follicular Lymphoma 1 (FL1)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma 1

MalaCards integrated aliases for Follicular Lymphoma 1:

Name: Follicular Lymphoma 1 56 29
Follicular Lymphoma, Susceptibility to, 1 56 13
Lymphoma, Follicular, Type 1 39
Lymphoma, Follicular 71
Follicular Lymphoma 58
Fl1 56

Characteristics:

Orphanet epidemiological data:

58
follicular lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

OMIM 56 613024
MESH via Orphanet 44 D008224
UMLS via Orphanet 72 C0024301
Orphanet 58 ORPHA545
MedGen 41 C2751665
UMLS 71 C0024301

Summaries for Follicular Lymphoma 1

OMIM : 56 Follicular non-Hodgkin lymphoma is an indolent B-cell malignancy with an annual incidence exceeding 10,000 cases in the United States (Bohen et al., 2003). One form of susceptibility to follicular lymphoma (FL1) is associated with a region on chromosome 6p21.33. (613024)

MalaCards based summary : Follicular Lymphoma 1, also known as follicular lymphoma, susceptibility to, 1, is related to lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Follicular Lymphoma 1 is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Immune response NFAT in immune response and Direct p53 effectors. The drugs Entecavir and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are lymphoma and splenomegaly

Related Diseases for Follicular Lymphoma 1

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 lymphoma 31.6 BCL6 BCL2 BCL10
2 nodal marginal zone b-cell lymphoma 31.3 BCL6 BCL2
3 primary central nervous system lymphoma 31.1 BCL6 BCL2
4 mantle cell lymphoma 30.6 IGH BCL6 BCL2 BCL10
5 lymphoma, hodgkin, classic 30.6 BCL6 BCL2
6 primary mediastinal large b-cell lymphoma 30.5 BCL6 BCL2
7 intravascular large b-cell lymphoma 30.5 BCL6 BCL2
8 marginal zone b-cell lymphoma 30.5 BCL6 BCL2 BCL10
9 b-cell lymphoma 30.4 IGH BCL6 BCL2 BCL10
10 t-cell/histiocyte rich large b cell lymphoma 30.3 IGH BCL6
11 nodal marginal zone lymphoma 30.3 IGH BCL6
12 follicular lymphoma 30.1 IGH FL1 BCL6 BCL2 BCL10
13 lymphosarcoma 29.9 IGH BCL6 BCL2
14 leukemia, chronic lymphocytic 29.7 IGH BCL6 BCL2 BCL10
15 lymphoma, non-hodgkin, familial 29.5 IGH HLA-DRB1 BCL6 BCL2 BCL10
16 reticulosarcoma 29.5 IGH BCL6 BCL2
17 leukemia, acute lymphoblastic 29.5 IGH BCL6 BCL2
18 lymphoma, mucosa-associated lymphoid type 29.4 IGH BCL6 BCL2 BCL10
19 primary mediastinal b-cell lymphoma 29.4 BCL6 BCL2
20 precursor t-cell acute lymphoblastic leukemia 29.3 IGH BCL10
21 primary cutaneous follicle center lymphoma 11.9
22 histiocytic and dendritic cell cancer 11.6
23 diffuse large b-cell lymphoma 11.4
24 burkitt lymphoma 11.1
25 lymphoblastic lymphoma 10.9
26 lymphoma aids related 10.9
27 lymphomatoid granulomatosis 10.9
28 splenic marginal zone lymphoma 10.9
29 leukemia, acute lymphoblastic 3 10.9
30 plasmablastic lymphoma 10.8
31 diffuse large b-cell lymphoma of the central nervous system 10.8
32 lymphocytic leukemia 10.7
33 neutropenia 10.6
34 myelodysplastic syndrome 10.4
35 b-cell non-hodgkin lymphoma 10.4
36 splenomegaly 10.4
37 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4
38 primary cutaneous marginal zone b-cell lymphoma 10.4
39 alk-positive large b-cell lymphoma 10.4
40 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 10.4
41 splenic diffuse red pulp small b-cell lymphoma 10.4
42 diffuse large b-cell lymphoma with chronic inflammation 10.4
43 lymphoplasmacytic lymphoma without igm production 10.4
44 chromosomal triplication 10.4
45 lymphoproliferative syndrome 10.4
46 leukemia, acute myeloid 10.3
47 graft-versus-host disease 10.3
48 myeloma, multiple 10.3
49 leukemia 10.3
50 thrombocytopenia 10.3

Graphical network of the top 20 diseases related to Follicular Lymphoma 1:



Diseases related to Follicular Lymphoma 1

Symptoms & Phenotypes for Follicular Lymphoma 1

Human phenotypes related to Follicular Lymphoma 1:

58 31 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphoma 58 31 Very frequent (99-80%) HP:0002665
2 splenomegaly 58 Frequent (79-30%)
3 fatigue 58 Frequent (79-30%)
4 fever 58 Very frequent (99-80%)
5 weight loss 58 Very frequent (99-80%)
6 lymphedema 58 Occasional (29-5%)
7 meningitis 58 Occasional (29-5%)
8 mediastinal lymphadenopathy 58 Very frequent (99-80%)
9 lymphadenopathy 58 Very frequent (99-80%)
10 abnormality of the peritoneum 58 Occasional (29-5%)
11 pleural effusion 58 Occasional (29-5%)
12 skin nodule 58 Occasional (29-5%)
13 night sweats 58 Very frequent (99-80%)

Clinical features from OMIM:

613024

Drugs & Therapeutics for Follicular Lymphoma 1

Drugs for Follicular Lymphoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 467)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
4
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
7
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
8 Orange Approved Phase 3
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Ribavirin Approved Phase 3 36791-04-5 37542
11
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
13 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
14
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
15
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
16
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Teniposide Approved Phase 3 29767-20-2 34698
20
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
21
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
22
leucovorin Approved Phase 3 58-05-9 6006 143
23
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
26
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
27
Dalteparin Approved Phase 3 9005-49-6
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
30
Ofloxacin Approved Phase 3 82419-36-1 4583
31
Idarubicin Approved Phase 3 58957-92-9 42890
32
Acetaminophen Approved Phase 3 103-90-2 1983
33
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
34
Promethazine Approved, Investigational Phase 3 60-87-7 4927
35
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
36
Piperacillin Approved Phase 3 66258-76-2 43672
37
Tazobactam Approved Phase 3 89786-04-9 123630
38
Vancomycin Approved Phase 3 1404-90-6 441141 14969
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
41
Captopril Approved Phase 3 62571-86-2 44093
42
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
43
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
44
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
45
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
46
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
47
ofatumumab Approved Phase 3 679818-59-8 6918251
48
Idelalisib Approved Phase 3 870281-82-6
49
Pixantrone Approved, Investigational Phase 3 144510-96-3
50
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478

Interventional clinical trials:

(show top 50) (show all 1141)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
4 A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma Recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine
5 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
6 Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial Unknown status NCT00028691 Phase 3 chlorambucil
7 Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
8 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
9 Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
10 MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA Unknown status NCT00435955 Phase 3 Rituximab
11 Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
12 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
13 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
14 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
15 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
16 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
17 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
18 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
19 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
20 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
21 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
22 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
23 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
24 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
26 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
27 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
28 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
29 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
30 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
31 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Completed NCT02213263 Phase 3
32 FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden Completed NCT00136552 Phase 3 rituximab
33 Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy Completed NCT00140582 Phase 3 Rituximab
34 A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen Completed NCT02569996 Phase 3 Rituximab
35 A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma Completed NCT02162771 Phase 3 Cyclophosphamide;Vincristine;Prednisone
36 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
37 Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden Completed NCT00696735 Phase 3
38 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
39 A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
40 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
41 Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial Completed NCT00185393 Phase 3
42 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
43 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
44 Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial Completed NCT00227695 Phase 3
45 Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
46 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
47 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
48 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
49 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
50 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3

Search NIH Clinical Center for Follicular Lymphoma 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ibritumomab tiuxetan

Genetic Tests for Follicular Lymphoma 1

Genetic tests related to Follicular Lymphoma 1:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 1 29

Anatomical Context for Follicular Lymphoma 1

MalaCards organs/tissues related to Follicular Lymphoma 1:

40
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Liver, Breast

Publications for Follicular Lymphoma 1

Articles related to Follicular Lymphoma 1:

(show all 28)
# Title Authors PMID Year
1
Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. 56
23791106 2013
2
Integrating GWAS and expression data for functional characterization of disease-associated SNPs: an application to follicular lymphoma. 56
23246294 2013
3
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. 56
20639881 2010
4
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. 56
19620980 2009
5
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. 56
12571354 2003
6
BCL2 translocation frequency rises with age in humans. 56
8090743 1994
7
bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. 56
2648153 1989
8
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. 56
3287162 1988
9
The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. 56
2965608 1988
10
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. 56
3110950 1987
11
Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. 56
3537802 1987
12
Involvement of the bcl-2 gene in human follicular lymphoma. 56
3874430 1985
13
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. 56
6334305 1984
14
Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. 56
6605167 1983
15
Mapping of an endogenous retroviral sequence to human chromosome 18. 56
6843662 1983
16
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. 56
7133054 1982
17
Use of Smooth Muscle Myosin Heavy Chain as an Effective Marker of Follicular Dendritic Cells. 61
28549038 2019
18
Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. 61
29086453 2018
19
The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. 61
26352106 2016
20
Primary gastrointestinal lymphomas - A study of 81 Cases from a Tertiary Healthcare Centre. 61
25494124 2014
21
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. 61
22496164 2012
22
Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. 61
21736867 2012
23
[Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. 61
20079011 2009
24
Expression of p63 in reactive hyperplasias and malignant lymphomas. 61
16224147 2005
25
Extranodal malignant lymphoma of the upperaerodigestive tract in King Chulalongkorn Memorial Hospital according to WHO classification. 61
16083197 2004
26
[Primary gastric lymphoma]. 61
15483686 2004
27
Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer. 61
12400605 2002
28
Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia. 61
1101936 1975

Variations for Follicular Lymphoma 1

ClinVar genetic disease variations for Follicular Lymphoma 1:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.427_428dup (p.Glu145fs)duplication Pathogenic 6253 rs587776632 1:85733583-85733584 1:85267900-85267901
2 BCL10 NM_003921.5(BCL10):c.231dup (p.Gly78fs)duplication Pathogenic 6254 rs587776633 1:85736415-85736416 1:85270732-85270733
3 BCL10 NM_003921.5(BCL10):c.525_541del (p.Val176fs)deletion Pathogenic 6255 rs587776634 1:85733471-85733487 1:85267788-85267804
4 BCL10 NM_003921.5(BCL10):c.410del (p.Asn137fs)deletion Pathogenic 6256 rs587776635 1:85733602-85733602 1:85267919-85267919
5 BCL10 NM_003921.5(BCL10):c.398dup (p.Ser134fs)duplication Pathogenic 6257 rs587776636 1:85733613-85733614 1:85267930-85267931
6 BCL10 NM_003921.5(BCL10):c.629_631AAG[2] (p.Glu212del)short repeat Pathogenic 6258 rs587776637 1:85733375-85733377 1:85267692-85267694

Expression for Follicular Lymphoma 1

Search GEO for disease gene expression data for Follicular Lymphoma 1.

Pathways for Follicular Lymphoma 1

Pathways related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.69 IGH HLA-DRB1 BCL10
2 11.52 BCL6 BCL2
3 11.43 BCL6 BCL2
4 11.38 BCL6 BCL2
5
Show member pathways
11.29 HLA-DRB1 BCL10
6 11.16 BCL2 BCL10
7 11.05 HLA-DRB1 BCL2 BCL10

GO Terms for Follicular Lymphoma 1

Biological processes related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.5 HLA-DRB1 BCL6 BCL10
2 negative regulation of cell growth GO:0030308 9.37 BCL6 BCL2
3 cell morphogenesis GO:0000902 9.26 BCL6 BCL2
4 B cell differentiation GO:0030183 9.16 BCL6 BCL2
5 positive regulation of B cell proliferation GO:0030890 8.96 BCL6 BCL2
6 regulation of apoptotic process GO:0042981 8.8 BCL6 BCL2 BCL10

Molecular functions related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 BCL2 BCL10

Sources for Follicular Lymphoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....